Skip to Main Content

An official website of the United States government

Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit  cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at OPM.gov.

Impact of Prostatitis and Benign Prostate Hyperplasia (BPH) on risk factors for Prostate Cancer

Principal Investigator
Name
Andrew Marks
Degrees
M.S., M.A.
Institution
Claremont Graduate University
Position Title
Data Scientist
Email
About this CDAS Project
Study
PLCO (Learn more about this study)
Project ID
PLCO-641
Initial CDAS Request Approval
Jul 17, 2020
Title
Impact of Prostatitis and Benign Prostate Hyperplasia (BPH) on risk factors for Prostate Cancer
Summary
Examine the relationship between previous health issues related to the prostate and the risk of prostate cancer (PCa) in patients. Specifically, is a patient history of an enlarged prostate (Benign Prostate Hyperplasia or BPH) or prostatitis associated with higher occurrences of PCa, how does mortality differ for patients with this medical history, should screening such as prostate-specific antigen (PSA) begin earlier for men who a history of these prostate related health issues.
Aims

Is there a higher occurrence of PCa in men with previous prostate related health issues?
Is there a difference in mortality rates for patients with previous prostate related health issues?
Is there a difference in severity in men with previous prostate related health issues?
What are the mortality differences in early detection by looking at ages of when screening takes place?

Collaborators

Andrew Marks, Claremont Graduate University